文献速递白血病造血干细胞移植与细胞治疗

单剂吉妥珠单抗奥唑米星(4.5 mg/m2)联合氟达拉滨、阿糖胞苷和蒽环类作为复发或难治性儿童急性髓系白血病再诱导治疗

Single-dose (4.5 mg/m2 ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2022-04-19

这项回顾性多中心研究评估了2008年2月至2019年8月间29例首次复发(n=26)或难治(n=3)儿童急性髓系白血病患者,接受单剂吉妥珠单抗奥唑米星4.5 mg/m2联合氟达拉滨、阿糖胞苷和蒽环类再诱导治疗。缓解率为83%(24/29),20例(69%)接受异基因移植,中位随访1.2年总生存率49%(95%CI=33;72)。作者认为该方案再诱导疗效好且安全性可接受,但需更大前瞻性研究。

要点

  • 29例复发/难治儿童AML接受单剂GO 4.5 mg/m2联合FLA-蒽环类再诱导,缓解率83%(24/29)。
  • 20例(69%)后续接受异基因移植,中位随访1.2年总生存率49%(95%CI=33;72)。
  • 最常见不良事件为发热性中性粒细胞减少伴微生物学证实占55%,肝静脉闭塞病6例(21%)。

核心结论

  • GO联合FLA-蒽环类化疗似乎是复发或难治性AML的良好再诱导方案,安全性较好。
  • 这些结果需更大规模的前瞻性研究验证。

研究设计与样本

  • 回顾性多中心研究,纳入2008年2月至2019年8月间29例儿童患者,其中首次复发26例、难治性疾病3例。
  • 干预为单剂吉妥珠单抗奥唑米星4.5 mg/m2联合氟达拉滨、阿糖胞苷和蒽环类。

主要发现

  • 缓解率为83%(24/29例儿童)。
  • 20例儿童(69%)接受了异基因移植。
  • 中位随访1.2年(范围0.1-8年),总生存率为49%(95%CI=33;72)。
  • 最常见不良事件为发热性中性粒细胞减少,55%的病例有微生物学鉴定。
  • 肝静脉闭塞病发生于6例患者(21%),其中5例在骨髓移植后发生,并在2-32天内缓解(中位10.5天)。

临床怎么用

  • 作者认为GO联合FLA-蒽环类化疗似乎是复发或难治性AML的良好再诱导方案,安全性较好。
  • 作者指出这些结果需更大规模的前瞻性研究验证。

局限性

  • 原文未报告局限性。
  • 作者在结论中写明这些结果需更大规模的前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite major therapeutic improvements, children with relapsed/refractory Acute Myeloid Leukaemia still have poor outcomes and overall survival does not exceed 40%. New treatments are required to improve their outcome; Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate antibody, is a potent cytotoxic agent whose efficacy has been demonstrated mainly in adults. The main objective of this retrospective multicentre study was to assess the outcome of children treated, between February 2008 and August 2019, with GO at a single 4.5 mg/m2 dose, in combination with Fludarabine, Cytarabine and antssshracyclines, in context of a first relapse (n = 26) or refractory disease (n = 3). The remission rate was 83% (24/29 children) and 20 children (69%) were allografted. With a median follow-up of 1.2 years (range: 0.1-8), the overall survival was 49% (CI95% = 33; 72). Most common adverse event was febrile neutropenia with microbiological identification in 55% of cases. Veno-occlusive disease occurred in 6 patients (21%), of which 5 subvened after bone marrow transplantation, and resolved within 2-32 days (median 10.5 days). Administration of GO in combination with FLA-anthracyclines chemotherapy appears to be a good reinduction regimen for relapsed or refractory AML with a good safety profile. These results warrant larger prospective study.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dhunputh C, Strullu M, Petit A, et al. Single-dose (4.5 mg/m2 ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia. Br J Haematol. 2022. PMID: 35438187. doi:10.1111/bjh.18203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。